Value Assessment in the Regulatory Context

Value in Health

Volumn 20, Issue 2, 2017, Pages 296-298

  Miller, Kathleen L ^a,b   Woodcock, Janet ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

FDA; pharmaceuticals; regulation; value assessment

Indexed keywords

ARTICLE; CLINICAL DECISION MAKING; DRUG CONTROL; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; PATIENT PARTICIPATION; PATIENT SAFETY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; DECISION MAKING; DRUG APPROVAL; LEGISLATION AND JURISPRUDENCE; PURCHASING; UNITED STATES;

DECISION MAKING; DRUG APPROVAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VALUE-BASED PURCHASING;

EID: 85013682770     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.11.010     Document Type: Article

References (7)

1. [1] Friedman, M.A., Woodcock, J., Lumpkin, M.M., et al. The safety of newly approved medicines: do recent market removals mean there is a problem?. JAMA 281 (1999), 1728–1734.
2. [2] Moore, T.J., Singh, S., Furberg, C.D., The FDA and new safety warnings. Arch Intern Med 172 (2012), 78–80.
3. [3] US Food and Drug Administration. Guidance for Industry. Expediated Programs for Serious Conditions—Drugs and Biologics. 2014, US Food and Drug Administration, Silver Spring, MD.
4. [4] Johnson, F.R., Zhou, M., Patient preferences in regulatory benefit-risk assessments: a US perspective. Value Health 19 (2016), 741–745.
5. [5] US Food and Drug Administration. The voice of the patient: a series of reports from FDA's Patient-Focused Drug Development Initiative. 2016. Available from: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm368342.htm. [Accessed July 20, 2016].
6. [6] US Food and Drug Administration. Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making: Draft PDUFA V Implementation Plan—February 2013. 2013, US Food and Drug Administration, Silver Spring, MD.
7. [7] Raju, G.K., Gurumurthi, K., Domike, R., et al. A benefit risk analysis approach to capture regulatory decision-making: non-small cell lung cancer. Clin Pharmacol Ther 100 (2016), 672–684.